Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02423512 · ClinicalTrials.gov registry record
The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness
A clinical trial, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 50
- Enrollment target
NCT02423512 is a clinical trial that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 50 participants.
The verdict
NCT02423512 has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
Vedolizumab is a new medication being used for the treatment of Crohn's disease and Ulcerative colitis. It works by blocking specific white blood cells (alpha 4-beta7 lymphocytes) from migrating to areas of inflammation in the gastrointestinal tract. Previous studies have shown that patients who have previous exposure to another type of medication for Crohn's disease and Ulcerative colitis (anti-TNF medications) do not respond to vedolizumab as well as those who have never been exposed. This study will investigate biologic markers in the blood and tissue the help identify possible reasons for this difference.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2015-06 |
| Est. Completion | 2017-06-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02423512
The ClinicalTrials.gov registry entry for NCT02423512 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02423512 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02423512 about?
NCT02423512 is a clinical study titled "The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness". Vedolizumab is a new medication being used for the treatment of Crohn's disease and Ulcerative colitis. It works by blocking specific white blood cells (alpha 4-beta7 lymphocytes) from migrating to areas of inflammation in the gastrointestinal tract. Previous studies have shown that patients who hav...
What is the current status of trial NCT02423512?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2015-06. Estimated completion is 2017-06-13.
Who is sponsoring clinical trial NCT02423512?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.